Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo Inks Screening Deal with Daiichi Sankyo

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies today said that it has entered into a long-term cancer drug screening pact with Japanese pharmaceutical firm Daiichi Sankyo.

Martinsried, Germany-based Kinaxo said that Daiichi Sankyo will use its chemical proteomics technologies Cellular Target Profiling and KinAffinity, as well as its phosphoproteomics technology PhosphoScout in various research programs.

Financial and other terms, including the length of the agreement, were not disclosed.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.